Latest News about NVS
Recent news which mentions NVS
From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   This group of stocks is flagging a rebound, and that’s good news for the S&P 500, says technical analyst
   
  
  
  March 22, 2022
  From MarketWatch
 From Motley Fool
 
   2 Top Stocks to Buy in March and Hold Forever
   
  
  
  March 15, 2022
  From Motley Fool
 
   Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study
   
  March 14, 2022
  Tickers 
   NVS
  
  
  From Benzinga
 From Benzinga
 From Benzinga
 
   3 No-Brainer Stocks to Buy With $1,000 Right Now
   
  
  
  March 14, 2022
  From Motley Fool
 From Benzinga
 
   NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
   
  March 10, 2022
  Tickers 
   NVS
  
  
  From Benzinga
 
   7 Drug Stocks To Consider After the Viatris Plunge
   
  
  
  March 10, 2022
  From InvestorPlace
 From Benzinga
 
   Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
   
  
  
  March 08, 2022
  From Benzinga
 
   Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
   
  
  
  March 07, 2022
  From Benzinga
 
   Viatris Just Snagged a Major FDA Approval
   
  
  
  March 03, 2022
  From Motley Fool
 
   Consumer Spending, E-Commerce, and the Business of Lodging
   
  
  
  March 02, 2022
  From Motley Fool
 From Benzinga
 
   This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
   
  
  
  February 23, 2022
  From Benzinga
 
   The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
   
  
  
  February 18, 2022
  From Benzinga
 From Benzinga
 
   New FDA program could boost drug development for rare diseases
   
  
  
  February 15, 2022
  From MarketWatch
 
   3 High-Yield Dividend Stocks to Buy and Hold for Decades
   
  
  
  February 12, 2022
  From Motley Fool
 
   Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
   
  
  
  February 10, 2022
  From Benzinga
 
   The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
   
  
  
  February 10, 2022
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
